Given that IL-18 is known to induce anti-tumor immunity, but based upon these data may also concomitantly increase A2AR expression, we hypothesized that suppression mediated by A2AR signaling may limit the overall therapeutic effect of IL-18. The gene discussed is ADORA2A; the disease is neoplasm.